Real-life outcome of anti-tumor necrosis factor &alpha; in the ambulatory treatment of ulcerative colitis

doi:10.3748/wjg.v21.i11.3282

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6552)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

551

WORD

279

HTML

3171

Figures (1-2)

151

Tables (1-4)

147

Sum=4299

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1041

Download

1212

Sum=2253

Mar 21, 2015 (publication date) through Apr 17, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 21, 2015; 21(11): 3282-3290
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3282

Full Size Figure Download Figure

Figure 2 Side effects of infliximab treatment (A) and adalimumab treatment (B).

Citation: Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290
URL: https://www.wjgnet.com/1007-9327/full/v21/i11/3282.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i11.3282